The interactive programme for CEPAS 2026 is online!
Explore sessions, topics, and activities that will bring
together experts from across Europe.
https://t.co/JaHbVWiZkj
Lyon, France, 28–31 October
Join @EBNEO in Lyon and be part of #CEPAS2026#neotwitter#neoEBM@ESPR_ESN
Deschmann et al. conducted a population-based cohort study from the Swedish Neonatal Quality Register included preterm newborns to determine the associations between phototherapy and neonatal mortality or morbidity.
https://t.co/SbI58SSmxy
#EBNeoAlerts#NeoEBM
Mitra et al. conducted a multicentre pilot RCT to assess feasibility of recruitment and compare clinical outcomes in a trial of early selective treatment of a moderate–severe PDA or no intervention in extremely preterm infants.
https://t.co/meCSt8ZvCw
#EBNeoAlerts#NeoEBM
Shridhar et al. conducted a randomized controlled trial in late preterm and term neonates requiring phototherapy to compare the rate of bilirubin decline between intermittent and continuous phototherapy.
https://t.co/FSzb9EaT9W
A new RCT led @annaevah from Sweden evaluates a parent–infant interaction intervention vs standard follow-up in extremely preterm infants
https://t.co/UeGAVEhsnh
#EBNEOAlerts#neoEBM
Rasmussen Vs. Devlin:
Which RCT posted by @EBNeo during April is most likely to impact your practice?
Vote is now open for our #IAOTM
https://t.co/fCtGu5tOvE
#EBNeoPolls
Once the glow from @PASMeeting wears off, start planning your next conference and join us for #CEPAS2026 in Lyon, France October 28th - 31st. @EBNEO will be there highlighting neonatal clinical research. Join us and @ESPR_ESN!
Register here: https://t.co/AALanmasJN
Prospective study of pulse oximetry accuracy and disparities by skin pigmentation (NeoPODS) compares SpO2 monitoring with SaO2 overall, and compares bias by race and pigmentation subgroups. @JPediatr@NeoSatyan#neotwitter#EBNEOalerts#neoEBM https://t.co/ETJyAqRAPf
Announcing the EBNEO Impact Article of the Year for 2025:
Expectant Management vs Medication for Patent Ductus Arteriosus in Preterm Infants
The PDA Randomized Clinical Trial by Laughon et al for the NICHD NRN
https://t.co/uur6f6nD2B
#EBNEO#IAOTY2025#neoEBM
Minor correction to the conclusions - it reduced the time to medical readiness for discharge for the ESC cohort, and 65% in the symptoms-based group avoided scheduled tapers.
Results of the OPTImize NOW clinical trial, presented yesterday at @PASMeeting and published concurrently in @JAMA_current compare a symptoms-based dosing approach to scheduled tapers in infants with NOWS. #EBNEOalerts#neotwitter#neoEBM https://t.co/hKWH7LEpCi
Two year follow-up of the SafeBoosC-3 Multicenter RCT of cerebral NIRS <72 HOL extremely preterm infants did not show any difference in the primary outcome of death or moderate/severe NDD. @JAMAPediatrics#neotwitter#neoEBM#EBNEOalerts https://t.co/ry2gdl8XNP
‼️ Abstract Deadline Extended ‼️
Abstract deadline for #CEPAS2026 was extended, but don't miss the deadline today! Submit your work, and join us in Lyon, France in October.
Submit now: https://t.co/Sj79M7LWbV
@EAPaediatrics@ESPR_ESN#neotwitter#neoEBM
The @EBNeo 2025 Impact Article of the Year race is down to the final two!
After a high-stakes first round, these 2 RCTs have emerged as the frontrunners:
Faix et al.
Laughon et al.
Vote now to crown the winner! 🗳️
⏳ Open for 5 days only!
https://t.co/8dyKF3mh37